MASCC Antiemetic Guidelines©
MASCC/ESMO Antiemetic Guidelines 2013
© 2013 MASCC™ All rights reserved worldwide.
Organizing and Overall Meeting Chairs:
Richard J. Gralla, MD, Fausto Roila, MD, Maurizio Tonato, MD, Jørn Herstedt, MD
On behalf of the ESMO/MASCC Guidelines Working Group, the updated antiemetic guidelines have been published in the Annals of Oncology. Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. F. Roila, J. Herrstedt, M. Aapro, R.J. Gralla, et al. , Annals of Oncology 21 (Supplement 5): v232 - v243, 2010
Antiemetic Guidelines 2010 of the MASCC Antiemetic Study Group
Courtesy of MASCC and Springer, the updated full text version of the MASCC/ESO Antiemetic Guidelines papers found in Supportive Care in Cancer, vol. 19, Supplement 1/March 2011. >>View Articles
The papers in this edition of Supportive Care in Cancer represent a detailed summary of the deliberations from the consensus guideline meeting which took place in Perugia, Italy in June 2009. Please refer to the PowerPoint guideline presentation for the most recent, and updated version of the MASCC/ESMO Antiemetic Guideline.
MASCC Endorsed Guideline Partnerships
Acute AINV Guideline
From the Pediatric Oncology Group of Ontario (POGO)
Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients
The purpose of this guideline is to provide health care providers with an approach to the prevention of acute antineoplastic-induced nausea and vomiting (AINV) in children who are receiving antineoplastic medication. The scope is limited to the prevention of AINV in the acute phase (within 24 hours of administration of an antineoplastic agent).